The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Venlafaxine Extended Release vs Placebo and Paroxetine in Social Anxiety Disorder
Abstract
BACKGROUND: Evidence indicates that venlafaxine hydrochloride extended release (ER) effectively ameliorates anxiety symptoms. OBJECTIVES: To evaluate the efficacy, safety, and tolerability of flexible-dose venlafaxine ER compared with placebo in the short-term treatment of generalized social anxiety disorder and, secondarily, to compare paroxetine with venlafaxine ER and paroxetine with placebo. DESIGN: Adult outpatients with DSM-IV generalized social anxiety disorder for 6 months or longer were randomly assigned to receive venlafaxine hydrochloride ER (75-225 mg/d), paroxetine (20-50 mg/d), or placebo for 12 weeks or less at 26 centers in the United States. The primary outcome measure was the total Liebowitz Social Anxiety Scale score. Secondary measures included response (Clinical Global Impression-Improvement score, 1 or 2) rates and Clinical Global Impression-Severity of Illness and Social Phobia Inventory scores. RESULTS: Of 440 patients treated, 413 (93.9%) were included in the last-observation-carried-forward efficacy analysis; of the 429 patients in the safety population, 318 (74.1%) completed the study. Mean daily doses were 201.7 mg (SD, 38.1 mg) of venlafaxine hydrochloride ER and 46.0 mg (SD, 7.9 mg) of paroxetine. Venlafaxine ER treatment was significantly superior to placebo at weeks 1 through 12 on the Liebowitz Social Anxiety Scale and Social Phobia Inventory and at week 2 and weeks 6 through 12 for Clinical Global Impression-Severity of Illness and responder status, and was significantly superior to paroxetine treatment at weeks 1 and 2 for the Social Phobia Inventory (P < .05 for all). Paroxetine treatment was significantly superior to placebo at weeks 3 through 12 on the Liebowitz Social Anxiety Scale, the Clinical Global Impression-Severity of Illness scale, and the Social Phobia Inventory, and at weeks 4 through 12 for response (P < .05 for all). Week 12 response rates were significantly greater for the venlafaxine ER and paroxetine groups (58.6% and 62.5%, respectively) vs the placebo group (36.1%) (P < .001 for both). CONCLUSION: Venlafaxine ER is effective in the short-term treatment of generalized social anxiety disorder, with efficacy and tolerability comparable to paroxetine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Psychometric properties of the Social Phobia Inventory (SPIN): New self-rating scale
Connor, K. M., Davidson, J. R. T., Churchill, L. E., Sherwood, A., Weisler, R. H., & Foa, E. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.4.379 · Cited by 1,624
Cognitive Behavioral Group Therapy vs Phenelzine Therapy for Social Phobia: 12-Week Outcome
Heimberg, R. G., Liebowitz, M. R., Hope, D. A., Schneier, F. R., Holt, C. S., Welkowitz, L. A., Juster, H. R., Campeas, R., Bruch, M. A., Cloitre, M., et al. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.12.1133 · Cited by 585
Self-citationSelective Alteration of Personality and Social Behavior by Serotonergic Intervention
Knutson, B., Wolkowitz, O. M., Cole, S. W., Chan, T., Moore, E. A., Johnson, R. C., Terpstra, J., Turner, R. A., & Reus, V. I. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.3.373 · Cited by 500
Phenelzine vs Atenolol in Social Phobia: A Placebo-Controlled Comparison
Liebowitz, M. R., Schneier, F., Campeas, R., Hollander, E., Hatterer, J., Fyer, A., Gorman, J., Papp, L., Davies, S., Gully, R., et al. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.49.4.290 · Cited by 444 · cited 1×
“Previous comparative studies of moclobemide and phenelzine 27 or atenolol and phen-elzine 26 had much smaller sample sizes, thereby limiting the generalizability and usefulness of the results.”
ResultSelf-citationCognitive-Behavioral and Pharmacological Treatments of Social Phobia: A Controlled Study
Gelernter, C. S. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810340070009 · Cited by 404
Social Phobia Subtypes in the National Comorbidity Survey
Kessler, R. C., Stein, M. B., & Berglund, P. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.5.613 · Cited by 398
Social phobia in general health care: an unrecognised undertreated disabling disorder
Weiller, E., Bisserbe, J. C., Boyer, P., Lepine, J. P., & Lecrubier, Y. (1996) · British Journal of Psychiatry · doi:10.1192/bjp.168.2.169 · Cited by 219
Responses of “generalized” and “discrete” social phobics during public speaking
Levin, A. P., Saoud, J. B., Strauman, T., Gorman, J. M., Fyer, A. J., Crawford, R., & Liebowitz, M. R. (1993) · Journal of Anxiety Disorders · doi:10.1016/0887-6185(93)90003-4 · Cited by 182
Self-citationAllgulander, C., Hackett, D., & Salinas, E. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.179.1.15 · Cited by 175
Walker, J. R., Van Ameringen, M. A., Swinson, R., Bowen, R. C., Chokka, P. R., Goldner, E., Johnston, D. C., Lavallie, Y.-J., Nandy, S., Pecknold, J. C., et al. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200012000-00009 · Cited by 84
Cited by
Stein, M. B., & Stein, D. J. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60488-2 · Cited by 1,137
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“Paroxetine [431,438-444] 1 Phenelzine [384,386,418,461,462] 1”
BackgroundBandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Bandelow, B., Bond, A., Davidson, J. R. T., den Boer, J. A., Fineberg, N. A., Knapp, M., Scott, J., et al. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105059253 · Cited by 617
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Attention training for generalized social anxiety disorder
Schmidt, N. B., Richey, J. A., Buckner, J. D., & Timpano, K. R. (2009) · Journal of Abnormal Psychology · doi:10.1037/a0013643 · Cited by 546
Stahl, S. M., Grady, M. M., Moret, C., & Briley, M. (2005) · CNS Spectrums · doi:10.1017/s1092852900019726 · Cited by 458
Long-Term Use of Antidepressants for Depressive Disorders and the Risk of Diabetes Mellitus
Andersohn, F., Schade, R., Suissa, S., & Garbe, E. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08071065 · Cited by 314
Warnke, A. (2014) · Psychiatric Drugs in Children and Adolescents · doi:10.1007/978-3-7091-1501-5_11 · Cited by 286
Hartford, J., Kornstein, S., Liebowitz, M., Pigott, T., Russell, J., Detke, M., Walker, D., Ball, S., Dunayevich, E., Dinkel, J., et al. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32807fb1b2 · Cited by 286
Self-citationSocial Anxiety Disorder: (532272011-001)
(2008) · PsycEXTRA Dataset · doi:10.1037/e532272011-001 · Cited by 258
Toward a neurobiology of psychotherapy: basic science and clinical applications
Etkin, A., Pittenger, C., Polan, H. J., & Kandel, E. R. (2005) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.17.2.145 · Cited by 244
Davidson, J., Rothbaum, B. O., Tucker, P., Asnis, G., Benattia, I., & Musgnung, J. J. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000222514.71390.c1 · Cited by 157
A Randomized Controlled Trial of Venlafaxine ER Versus Placebo in Pediatric Social Anxiety Disorder
March, J. S., Entusah, A. R., Rynn, M., Albano, A. M., & Tourian, K. A. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.02.025 · Cited by 156
Anxiety disorders: a comprehensive review of pharmacotherapies
Hoffman, E. J., & Mathew, S. J. (2008) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20041 · Cited by 149
Extrahypothalamic oxytocin neurons drive stress-induced social vigilance and avoidance
Duque-Wilckens, N., Torres, L. Y., Yokoyama, S., Minie, V. A., Tran, A. M., Petkova, S. P., Hao, R., Ramos-Maciel, S., Rios, R. A., Jackson, K., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2011890117 · Cited by 139
Systematic review and meta-analysis: dose-response curve of SSRIs and SNRIs in anxiety disorders
Jakubovski, E., Johnson, J. A., Nasir, M., Müller-Vahl, K., & Bloch, M. H. (2019) · Depression and Anxiety · doi:10.1002/da.22854 · Cited by 131
The evidence-based pharmacotherapy of social anxiety disorder
Blanco, C., Bragdon, L. B., Schneier, F. R., & Liebowitz, M. R. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000119 · Cited by 99
Self-citationWong, J., Gordon, E. A., & Heimberg, R. G. (2012) · Handbook of Evidence-Based Practice in Clinical Psychology · doi:10.1002/9781118156391.ebcp002027 · Cited by 96
Pharmacotherapy for social anxiety disorder (SAnD)
Williams, T., Hattingh, C. J., Kariuki, C. M., Tromp, S. A., van Balkom, A. J., Ipser, J. C., & Stein, D. J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001206.pub3 · Cited by 84
Evidence-based pharmacotherapy for personality disorders
Ripoll, L. H., Triebwasser, J., & Siever, L. J. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000071 · Cited by 83
Pan, S.-J., Tan, Y.-L., Yao, S.-W., Xin, Y., Yang, X., Liu, J., & Xiong, J. (2018) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.207 · Cited by 63
Defining Response and Remission in Anxiety Disorders: Toward an Integrated Approach
Bandelow, B. (2006) · CNS Spectrums · doi:10.1017/s1092852900025815 · Cited by 52
Meta-analysis: Risk of dry mouth with second generation antidepressants
Cappetta, K., Beyer, C., Johnson, J. A., & Bloch, M. H. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.12.012 · Cited by 49
Curtiss, J., Andrews, L., Davis, M., Smits, J., & Hofmann, S. G. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1285907 · Cited by 46
Nagata, T., Suzuki, F., & Teo, A. R. (2015) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12327 · Cited by 40
Liebowitz, M. R., Salman, E., Nicolini, H., Rosenthal, N., Hanover, R., & Monti, L. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.12101342 · Cited by 36
Swinson, R. P. (2005) · The Canadian Journal of Psychiatry · doi:10.1177/070674370505000601 · Cited by 17
Personalized Clinical Approaches to Anxiety Disorders
Perna, G., Alciati, A., Sangiorgio, E., Caldirola, D., & Nemeroff, C. B. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-32-9705-0_25 · Cited by 15
Rozen, N., & Aderka, I. M. (2020) · Clinical Psychology Review · doi:10.1016/j.cpr.2020.101874 · Cited by 5
Psychopharmacology for Social Anxiety Disorder
Blanco, C., Bragdon, L., Schneier, F. R., & Liebowitz, M. R. (2014) · Social Anxiety · doi:10.1016/b978-0-12-394427-6.00022-4 · Cited by 2
Self-citation
Metadata
- Authors
- Liebowitz, M. R., Gelenberg, A. J., & Munjack, D.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2005-02-01
- Volume
- 62
- Issue
- 2
- Pages
- 190
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2097731877
- Cited by
- 160
- References
- 11
- FWCI
- 23.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.